No Data Yet
HSBC downgraded Biogen (BIIB) to 'Reduce' with a $143 price target on December 10, citing concerns over declining royalty revenues.
China's new commercial drug insurance program will cut the price of Alzheimer's drug Leqembi by up to 50% from its current US$28,400 annual cost, impacting pharmaceutical firms like Eisai and Eli Lilly.